Absci announced a $50 million funding round led by Eli Lilly, with Lilly investing $40 million for equity in the Nasdaq-listed startup. Absci’s program focus includes developing a medication designed to spur hair growth, alongside potential additional therapeutic expansion such as endometriosis indications. The financing underscores how Lilly’s weight-loss cash flows are being redirected into adjacent therapeutic categories, pairing large-scale clinical know-how with AI-driven discovery capabilities housed in smaller specialized firms. For the sector, it reinforces a broader funding pattern where marquee pharma bankrolls platform companies to speed early discovery and build differentiated pipeline breadth beyond core franchises.